[ORGANIZATION]

SITC 2026

Featured in 1 tracked story · first seen 2 days ago

Situations

[ACTIVE] [BUSINESS] [KR] [US] [ES]

Samsung Bioepis SB27 Keytruda biosimilar development

3 clusters · 4 sources · last updated 2 days ago

Latest: Samsung Bioepis confirms clinical equivalence for Keytruda biosimilar SB27

Samsung Bioepis has advanced the development of SB27, a biosimilar candidate for the immunotherapy drug Keytruda. At the 2026 ESMO annual meeting, the company reported Phase 1 clinical trial results involving 163 non-sma